Ying Wen

Title: Ying Wen: Innovator in Tumor Neoantigen Detection

Introduction

Ying Wen is a prominent inventor based in Shenzhen, China. He has made significant contributions to the field of biomedicine, particularly in the detection of tumor neoantigens. His innovative approach has the potential to enhance cancer immunotherapy and diagnostics.

Latest Patents

Ying Wen holds a patent for a "Method and platform for detecting immunogenicity of tumor neoantigen." This patent describes a method that includes culturing human peripheral blood monocytes ex vivo for 13 days. During this period, an antigenic peptide fragment of the human influenza virus is added, along with stimulation and activation of cytokines, antigenic peptides, and immunoadjuvants. The process culminates in an enzyme-linked immunospot (ELISPOT) chromogenic reaction, followed by instrument-based scanning, counting, and analysis to detect the immunogenicity of tumor neoantigens. This method offers advantages such as a short detection period, high convenience, low consumption of experimental cells, and low detection costs, making it suitable for high-throughput assays in biomedicine.

Career Highlights

Ying Wen has worked with notable companies in the biotechnology sector, including Neocura Biomedical Technology Co., Ltd and Beijing Neocurna Biotechnology Corporation. His experience in these organizations has contributed to his expertise in the field of immunogenicity detection.

Collaborations

Ying Wen has collaborated with several professionals in his field, including Youdong Pan and Qi Song. These partnerships have likely enhanced his research and development efforts.

Conclusion

Ying Wen's innovative work in the detection of tumor neoantigens represents a significant advancement in biomedicine. His contributions have the potential to improve cancer diagnostics and treatment strategies.